We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?
Read MoreHide Full Article
Rhythm Pharmaceuticals, Inc. (RYTM - Free Report) shares soared 7.4% in the last trading session to close at $53.17. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.1% gain over the past four weeks.
Last month, Rhythm announced the FDA’s acceptance of the supplemental new drug application for its only marketed drug, Imcivree (setmelanotide), to treat obesity in children as young as two years old. The FDA granted Priority Review to the application. A final decision from the FDA is expected on Dec. 26, 2024. The stock price rally could be related to positive investors’ expectations regarding a favourable outcome.
This company is expected to post quarterly loss of $0.81 per share in its upcoming report, which represents a year-over-year change of -6.6%. Revenues are expected to be $32.2 million, up 43.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Rhythm Pharmaceuticals, the consensus EPS estimate for the quarter has been revised 2.4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on RYTM going forward to see if this recent jump can turn into more strength down the road.
Rhythm Pharmaceuticals is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Codexis (CDXS - Free Report) , finished the last trading session 10.9% higher at $3.16. CDXS has returned -5.3% over the past month.
For Codexis, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.25. This represents a change of +3.9% from what the company reported a year ago. Codexis currently has a Zacks Rank of #4 (Sell).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?
Rhythm Pharmaceuticals, Inc. (RYTM - Free Report) shares soared 7.4% in the last trading session to close at $53.17. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.1% gain over the past four weeks.
Last month, Rhythm announced the FDA’s acceptance of the supplemental new drug application for its only marketed drug, Imcivree (setmelanotide), to treat obesity in children as young as two years old. The FDA granted Priority Review to the application. A final decision from the FDA is expected on Dec. 26, 2024. The stock price rally could be related to positive investors’ expectations regarding a favourable outcome.
This company is expected to post quarterly loss of $0.81 per share in its upcoming report, which represents a year-over-year change of -6.6%. Revenues are expected to be $32.2 million, up 43.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Rhythm Pharmaceuticals, the consensus EPS estimate for the quarter has been revised 2.4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on RYTM going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Rhythm Pharmaceuticals is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Codexis (CDXS - Free Report) , finished the last trading session 10.9% higher at $3.16. CDXS has returned -5.3% over the past month.
For Codexis, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.25. This represents a change of +3.9% from what the company reported a year ago. Codexis currently has a Zacks Rank of #4 (Sell).